39 results
424B3
PRE
Prenetics Global Limited - Ordinary Shares
16 Feb 24
Prospectus supplement
6:13am
in the R&D phase, and may not be successful in our efforts to develop any of these or other products into marketable products. Any failure to develop … that are currently in the R&D phase, and may not be successful in our efforts to develop any of these or other products into marketable products. Any failure
F-3
PRE
Prenetics Global Limited - Ordinary Shares
17 Jan 24
Shelf registration (foreign)
6:59am
prospects could be materially and adversely affected.
We have pipeline products that are currently in the R&D phase, and may not be successful in our … be reduced and our revenue could be adversely affected.
We have pipeline products that are currently in the R&D phase, and may not be successful
424B3
PRE
Prenetics Global Limited - Ordinary Shares
2 Nov 23
Prospectus supplement
4:04pm
could be adversely affected.
We have pipeline products that are currently in the R&D phase, and may not be successful in our efforts to develop any … affect our business and future prospects.
We have pipeline products that are currently in the R&D stage. For certain of our pipeline products, before
POS AM
PRE
Prenetics Global Limited - Ordinary Shares
6 Oct 23
Prospectus update (post-effective amendment)
1:52pm
have pipeline products that are currently in the R&D phase, and may not be successful in our efforts to develop any of these or other products … prospects.
We have pipeline products that are currently in the R&D stage. For certain of our pipeline products, before obtaining approvals from regulatory
F-3
PRE
Prenetics Global Limited - Ordinary Shares
29 Sep 23
Shelf registration (foreign)
9:17am
, the demand for our testing services could be reduced and our revenue could be adversely affected.
We have pipeline products that are currently in the R&D … in the R&D stage. For certain of our pipeline products, before obtaining approvals from regulatory authorities for the marketing and sales
424B3
eucv68yd2gyykgsi 0o
21 Jul 23
Prospectus supplement
6:16am
POS AM
2kve3
6 Jul 23
Prospectus update (post-effective amendment)
9:00am
6-K
EX-99.1
eqe2xe
5 Jun 23
Prenetics Announces First Quarter 2023 Financial Results
7:18am
POS AM
x55wy4o7n homfty70c
31 May 23
Prospectus update (post-effective amendment)
8:25am
POS AM
5qgt9r5el23xyu
1 May 23
Prospectus update (post-effective amendment)
5:19pm
6-K
EX-99.1
turht0sffyrz24d5ya
16 Dec 22
Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology
8:06am
POS AM
5p6i9mka27kt2r0gfg
14 Dec 22
Prospectus update (post-effective amendment)
8:04am
424B3
oaz dgs888k5k
1 Jul 22
Prospectus supplement
4:10pm
F-1/A
vnlp3e73q0owh37b0f6p
28 Jun 22
Registration statement (foreign) (amended)
4:02pm
F-1/A
87qe09g3
21 Jun 22
Registration statement (foreign) (amended)
5:07pm
F-1/A
6zfy678dx2kc s7
10 Jun 22
Registration statement (foreign) (amended)
4:02pm
F-1
9vwbq3ynx3cl
27 May 22
Registration statement (foreign)
4:26pm
6-K
EX-99.1
7jyx8fg3tpbvruon
19 May 22
Current report (foreign)
6:27am
424B3
p39 9sxmj5h5bd
11 Apr 22
Prospectus supplement
6:03am